Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women

Assiut University

Status: Completed

Conditions: Polycystic Ovary Syndrome

Treatments: Drug: Metformin; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02910817

obgy-115-2014

Details and patient eligibility

About

RCT to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.

Enrollment: 102 patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The inclusion criteria restricted the patients to 39 years old with basal FSH < 10 IU/ml and normal TSH and prolacin.

Exclusion criteria

• Exclusion criteria were diabetes mellitus (excluded by GTT), renal or liver disease, associated male factor, documented tubal factor or pelvic adhesions, elevated 17 alfa hydroxyprogesterone level and FSH ≥10 IU/ml. We also excluded the women who started program or medications to reduce their weight and those who their partner has abnormal semen parameters according to the world health organization parameters (WHO, 2010)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

102 participants in 2 patient groups, including a placebo group

Metformin-treated group

Experimental group

Description:

51 overweight and obese women (BMI\>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle

Treatment:

Drug: Metformin

Placebo

Placebo Comparator group

Description:

A cohort of fifty-one cross matched PCOS women

Treatment:

Other: Placebo